Association of RUNX3 Methylation with Clinical Outcome and Cell Migration/Invasion in Laryngeal Squamous Cell Carcinoma

References

• Cattaruzza MS, Maisonneuve P, Boyle P. Epidemiology of laryngeal cancer. Eur J Cancer B Oral Oncol 1996;32B:293–305.
   PubMed Web of Science ®Google Scholar
• Chen K, Song F, He M, Li H, Qian B, Zhang W, et al. Trends in head and neck cancer incidence in Tianjin, China, between 1981 and 2002. Head Neck 2009;31:175–182.
   PubMed Web of Science ®Google Scholar
• Morshed K, Polz-Dacewicz M, Szymanski M, Polz D. Short-fragment PCR assay for highly sensitive broad-spectrum detection of human papillomaviruses in laryngeal squamous cell carcinoma and normal mucosa: clinico-pathological evaluation. Eur Arch Otorhinolaryngol 2008;265(Suppl 1):S89–S96.
   Google Scholar
• Li Z, Gao W, Lei W, Ho W, Chan Y, Wong T, et al. The diagnostic value of methylated DNA in laryngeal squamous cell carcinoma: meta-analysis. Head Neck Oncol 2013;5:15.
   Google Scholar
• Kada S, Hirano S, Tateya I, Kitamura M, Ishikawa S, Kanda T, et al. Ten years single institutional experience of treatment for advanced laryngeal cancer in Kyoto University. Acta Otolaryngol Suppl 2010;563:68–73.
   PubMedGoogle Scholar
• Stembalska A, Leszczyński P, Gil J, Ramsey D, Pitala G, Maciejczyk A, et al. Global DNA methylation status in laryngeal cancer. Head Neck. 2014;36:419–424.
   PubMed Web of Science ®Google Scholar
• Wong TS, Gao W, Li ZH, Chan JY, Ho WK. Epigenetic dysregulation in laryngeal squamous cell carcinoma. J Oncol 2012;2012:739461.
   PubMedGoogle Scholar
• Markowski J, Sieron AL, Kasperczyk K, Ciupinska-Kajor M, Augusciak-Duma A, Likus W. Expression of the tumor suppressor gene hypermethylated in cancer 1 in laryngeal carcinoma. Oncol Lett 2015;9:2299–2302.
   PubMed Web of Science ®Google Scholar
• Furuta T, Shuto T, Shimasaki S. DNA demethylation-dependent enhancement of toll-like receptor-2 gene expression in cystic fibrosis epithelial cells involves SP1-activated transcription. BMC Mol Biol 2008;9:39.
   PubMed Web of Science ®Google Scholar
• Severin PM, Zou X, Gaub HE, Schulten K. Cytosine methylation alters DNA mechanical properties. Nucleic Acids Res 2011;39:8740–8751.
   PubMed Web of Science ®Google Scholar
• Baylin SB, Herman JG. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet 2000;16:168–174.
   PubMed Web of Science ®Google Scholar
• Wu CT, Morris JR. Genes, genetics and epigenetics: a correspondence. Sciences 2001;293:1103–1105.
   Web of Science ®Google Scholar
• Ito Y. Oncogenic potential of the RUNX gene family: overview. Oncogene 2004;23:4198–4208.
   PubMed Web of Science ®Google Scholar
• Li QL, Ito K, Sakakura C, Fukamachi H, Noue K, Chi XZ. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 2002;109:113–124.
   PubMed Web of Science ®Google Scholar
• Yanada M, Yaoi T, Shimada J, Sakakura C, Nishimura M, Ito K. Frequent hemizygous deletion at 1p36 and hypermethylation down-regulate RUNX3 expression in human lung cancer cell lines. Oncol Rep 2005;14:817–822.
   PubMed Web of Science ®Google Scholar
• Sakakura C, Miyagawa K, Fukuda KI, Nakashima S, Yoshikawa T, Kin S. Frequent silencing of RUNX3 in esophageal squamous cell carcinomas is associated with radioresistance and poor prognosis. Oncogene 2007;26:5927–5938.
   PubMed Web of Science ®Google Scholar
• Zhang XY, He HR, Zhang X, Guo WJ, Wang YQ. RUNX3 promoter methylation is associated with hepatocellular carcinoma risk: a meta-analysis. Cancer Invest 2015;33:121–125.
   PubMed Web of Science ®Google Scholar
• Tan SH, Ida H, Lau QC, Goh BC, Chieng WS, Loh M, et al. Detection of promoter hypermethylation in serum samples of cancer patients by methylation-specific polymerase chain reaction for tumour suppressor genes including RUNX3. Oncol Rep 2007;18:1225–1230.
   PubMed Web of Science ®Google Scholar
• Nishio M, Sakakura C, Nagata T, Komiyama S, Miyashita A, Hamada T. RUNX3 promoter methylation in colorectal cancer: its relationship with microsatellite instability and its suitability as a novel serum tumor marker. Anticancer Res 2010;30:2673–2682.
   PubMed Web of Science ®Google Scholar
• Marioni G, Marchese-Ragona R, Cartei G, Marchese F, Staffieri A. Current opinion in diagnosis and treatment of laryngeal carcinoma. Cancer Treat Rev 2006;32:504–515.
   PubMed Web of Science ®Google Scholar
• Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010;17:1471–1474.
   PubMed Web of Science ®Google Scholar
• Wang D, Cui W, Wu X, Qu Y, Wang N, Shi B, et al. RUNX3 site-specific hypermethylation predicts papillary thyroid cancer recurrence. Am J Cancer Res 2014;4:725–737.
   PubMed Web of Science ®Google Scholar
• Xu Y, Wang K, Gao W, Zhang C, Huang F, Wen S, et al. MicroRNA-106b regulates the tumor suppressor RUNX3 in laryngeal carcinoma cells. FEBS Lett 2013;587:3166–3174.
   PubMed Web of Science ®Google Scholar
• Kim TY, Lee HJ, Hwang KS, Lee M, Kim JW, Bang YJ, et al. Methylation of RUNX3 in various types of human cancers and premalignant stages of gastric carcinoma. Lab Invest 2004;84:479–484
   PubMed Web of Science ®Google Scholar
• Tang J, Bai W, Ji W, Gao H, Liu J. Relationship between hypermethylation of Runx3 gene and the development and metastasis of laryngeal carcinoma. J Clin Otorhinolaryngol Head and Neck Surg. 2010;24:834–837.
   Google Scholar
• Subramaniam MM, Chan JY, Yeoh KG, Quek T, Ito K, Salto-Tellez M. Molecular pathology of RUNX3 in human carcinogenesis. Biochim Biophys Acta 2009;1796:315–331.
   PubMed Web of Science ®Google Scholar
• Pennison M, Pasche B. Targeting transforming growth factor-beta signaling. Curr Opin Oncol 2007;19:579–585
   PubMed Web of Science ®Google Scholar
• Roberts AB, Anzano MA, Wakefield LM, Roche NS, Stern DF, Sporn MB. Type beta transforming growth factor: a bifunctional regulator of cellular growth. Proc Natl Acad Sci USA 1985;82:119–123
   PubMed Web of Science ®Google Scholar
• Connolly EC, Freimuth J, Akhurst RJ. Complexities of TGF-beta targeted cancer therapy. Int J Biol Sci 2012;8:964–978
   PubMed Web of Science ®Google Scholar
• Chen F, Bai J, Li W, Mei P, Liu H, Li L, et al. RUNX3 suppresses migration, invasion and angiogenesis of human renal cell carcinoma. PLoS One 2013;8:e56241.
   Google Scholar
• Mei PJ, Bai J, Liu H, Li C, Wu YP, Yu ZQ, et al. RUNX3 expression is lost in glioma and its restoration causes drastic suppression of tumor invasion and migration. J Cancer Res Clin Oncol 2011;137:1823–1830
   PubMed Web of Science ®Google Scholar
• Hsu PI, Hsieh HL, Lee J, Lin LF, Chen HC, Lu PJ, et al. Loss of RUNX3 expression correlates with differentiation, nodal metastasis, and poor prognosis of gastric cancer. Ann Surg Oncol 2009;16:1686–1694
   PubMed Web of Science ®Google Scholar
• Hu Q, Yu L, Chen R, Wang YL, Ji L, Zhang Y, et al. 5-aza-2′-deoxycytidine improves the sensitivity of endometrial cancer cells to progesterone therapy. Int J Gynecol Cancer 2012;22:951–959.
   PubMed Web of Science ®Google Scholar
• Yang J, Zhu XB, He LX, Gu ZW, Jin MZ, Ji WY. Clinical significance of epigenetic silencing re-expression of O6-methylguanine DNA methyltransferase using epigenetic agents in laryngeal carcinoma. Oncol Lett 2015;9:35–42.
   PubMed Web of Science ®Google Scholar